Health Condition 1: H160- Corneal ulcer
Conditions
Interventions
Intervention1: Intervention 2 - Difluprednate 0.05% with moxifloxacin: Difluprednate 0.05% 4t/d for 1 week followed by tapering doses, decreased by 1 drop weekly for a total of 4 weeks of steroid ther
Sponsors
Dr Thomas M Lietman
Eligibility
Inclusion criteria
Inclusion criteria: 1. Corneal ulcer that is smear positive for typical bacteria (i.e. non-Nocardia or Mycobacteria) 2. Moderate to severe vision loss, defined as Snellen visual acuity of 20/40 or worse 3. Corneal thickness �300 µm, as measured on Anterior Segment-Optical Coherence Tomography 4. Basic understanding of the study as determined by the physician 5. Commitment to return for follow up visits
Exclusion criteria
Exclusion criteria: 1. Evidence of concomitant infection on exam, gram stain, or confocal microscopy (i.e. herpes, both bacteria and acanthameoba on gram stain) 2. Impending or frank perforation at recruitment 3. Involvement of sclera at presentation 4. Non-infectious or autoimmune keratitis 5. History of corneal transplantation or recent intraocular surgery 6. Pinhole visual acuity worse than 20/200 in the unaffected eye 7. Participants who are decisionally and/or cognitively impaired
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of Best-spectacle corrected visual acuity 3 months after enrollment in the study Timepoint: 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) To determine if early topical steroids are a beneficial adjuvant in the treatment of smear-positive bacterial ulcers. 2) To determine which ulcer characteristics predict the most benefit from the addition of adjuvant corneal cross-linking and/or early steroids.Timepoint: 3 months | — |
Countries
United States of America
Contacts
Public ContactDr N Venkatesh Prajna
Aravind Eye Hospital
Outcome results
None listed